# Study to Assess Cardiac Conduction of GSK1349572

> **NCT00996021** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 42 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** GSK1349572 250 mg
- **DRUG:** Placebo Suspension
- **DRUG:** Moxifloxacin 400 mg

## Key facts

- **NCT ID:** NCT00996021
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2009-11
- **Final completion:** 2009-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2010-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00996021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00996021, "Study to Assess Cardiac Conduction of GSK1349572". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00996021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*